Last updated 18 days ago
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
190 patients around the world
Available in Mexico, Argentina, Brazil
Eli Lilly and Company
21Research sites
190Patients around the world
This study is for people with
Arthritis
Juvenile idiopathic arthritis
Requirements for the patient
To 18 Years
All Gender
Medical requirements
- Participants must have completed a previous study of baricitinib for the treatment of JIA.
- Participants must not have had a permanent discontinuation of baricitinib in the prior study.Participants must have not developed an allergy to baricitinib.
Sites
Centro Médico Privado de Reumatología - San Miguel de Tucumán
Recruiting
Hospital General de Niños Pedro de Elizalde
Recruiting
Instituto CAICI - Rosario, Santa Fe
Recruiting
Centro de Investigaciones Médicas Tucumán
Recruiting
Instituto da Criança e do Adolescente - ICr HCFMUSP
Santa Casa de São Paulo (IPITEC) - Santa Casa Instituto de Pesquisa
Núcleo De Gestão De Pesquisa Clinica - NGP
Universidad Federal de São Paulo - Unifesp
Recruiting
Centro Mineiro de Pesquisa - CMIP
Recruiting
Faculdade de Medicina da Universidade Estadual Paulista - Campus de Botucatu - UNESP
Recruiting
StudyJUVE-X
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Juvenile idiopathic arthritis
Requirements
To 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT03773965
